Please ensure Javascript is enabled for purposes of website accessibility

Moderna's CEO Says Its Coronavirus Vaccine Will Be Affordable

By Mark Prvulovic - Updated Mar 5, 2020 at 11:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Stephane Bancel said in an interview that the price will be in line with that of other vaccines for similar conditions.

As the COVID-19 epidemic continues to spread, demand keeps growing for effective treatments and vaccines. Moderna (MRNA 0.70%), one of the only companies with a vaccine in clinical trials for SARS-CoV-2 (the coronavirus that causes the disease), made news Wednesday when its CEO said that his company's vaccine would be affordably priced.

Stephane Bancel said in an interview with Business Insider that he plans to price the SARS-CoV-2 vaccine, known as mRNA-1273, in line with other vaccines for respiratory infections. Although he didn't offer an exact figure, one can look to prices for other vaccines, such as a pneumonia treatment, Prevnar 13 which has an average cost of around $240, to get a rough idea of what Bancel might be thinking.

A person about to receive a COVID-19 vaccine.

Image source: Getty Images.

"We are highly aware this is a public-health issue, and so we will be very thoughtful about setting a price if this product gets to approval. There is no world I think where we would contemplate to price this higher than other respiratory virus vaccines," said Bancel.

The total number of confirmed COVID-19 diagnoses shot past 95,000 on Wednesday. While the growth rate of cases in mainland China appears to have slowed down, the numbers in countries such as South Korea, Italy, and Iran have surged in the past week.

The only other healthcare company with a COVID-19 treatment at the clinical-trial stage is Gilead Sciences. Resmdesivir, which was developed as an Ebola drug (and was insufficiently effective in that indication) has shown promise in terms of reducing symptoms in patients with COVID-19. Although it's unclear whether remdesivir will have any value as a preventative treatment, demand for the drug will likely be strong nonetheless.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$144.27 (0.70%) $1.01
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$63.08 (0.80%) $0.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.